During cell cycle progression, cyclin D1 and CDK2 are critical cell cycle regulators involved in the G0/G1 to S phase transition and serve as theraputic targets in several types of cancers, including NSCLC [41, 42]. The gene discussed is CDK2; the disease is non-small cell lung carcinoma.